Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Authors
Keywords
-
Journal
Therapeutic Advances in Endocrinology and Metabolism
Volume 12, Issue -, Pages 204201882098022
Publisher
SAGE Publications
Online
2021-01-15
DOI
10.1177/2042018820980225
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight
- (2020) William I. Sivitz et al. DIABETES CARE
- 1112-P: Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial
- (2020) KIERAN DOCHERTY et al. DIABETES
- Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial
- (2020) Matthew J. Crowley et al. DIABETES CARE
- Metformin and gut microbiota: their interactions and their impact on diabetes
- (2019) Natalia G. Vallianou et al. Hormones-International Journal of Endocrinology and Metabolism
- Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors
- (2019) Susan J. Bersoff-Matcha et al. ANNALS OF INTERNAL MEDICINE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis
- (2019) Yechen Han et al. Cardiovascular Diabetology
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
- (2019) Rozalina G. McCoy et al. Diabetes Technology & Therapeutics
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?
- (2019) Silvio E. Inzucchi et al. DIABETES OBESITY & METABOLISM
- Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach
- (2018) Josephine L. Harrington et al. Current Diabetes Reports
- Incidence of Dementia is Increased in Type 2 Diabetes and Reduced by the Use of Sulfonylureas and Metformin
- (2018) Chih-Cheng Hsu et al. JOURNAL OF ALZHEIMERS DISEASE
- Long-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes
- (2018) Tze Pin Ng et al. JOURNAL OF ALZHEIMERS DISEASE
- Association of metformin administration with gut microbiome dysbiosis in healthy volunteers
- (2018) Ilze Elbere et al. PLoS One
- Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
- (2018) Hsien-Yen Chang et al. JAMA Internal Medicine
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Differential effects of metformin on age related comorbidities in older men with type 2 diabetes
- (2017) Chen-Pin Wang et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation
- (2017) Sarah J. Mancini et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metformin extends C. elegans lifespan through lysosomal pathway
- (2017) Jie Chen et al. eLife
- Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
- (2017) Mirko Sikirica et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Metformin as a Tool to Target Aging
- (2016) Nir Barzilai et al. Cell Metabolism
- Citizen Petition to the US Food and Drug Administration to Change Prescribing Guidelines: The Metformin Experience: Table 1.
- (2016) Kasia J. Lipska et al. CIRCULATION
- Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249
- (2016) Sweety Agrawal et al. DIABETES CARE
- Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes
- (2016) Julio Rosenstock et al. DIABETES CARE
- Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials
- (2016) Dandan Li et al. DIABETES OBESITY & METABOLISM
- Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study
- (2016) Vanita R. Aroda et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling
- (2016) H. Dorota Halicka et al. Aging-US
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect
- (2015) Yoshifumi Saisho Endocrine Metabolic & Immune Disorders-Drug Targets
- Metformin in Patients With Type 2 Diabetes and Kidney Disease
- (2014) Silvio E. Inzucchi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Type 2 Diabetes and Antidiabetic Medications in Relation to Dementia Diagnosis
- (2014) Chin Cheng et al. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
- Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
- (2014) Anila K. Madiraju et al. NATURE
- Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation
- (2013) Olga Moiseeva et al. AGING CELL
- Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism
- (2013) Filipe Cabreiro et al. CELL
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage
- (2012) C. Algire et al. Cancer Prevention Research
- A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome
- (2012) Qiang Du et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
- (2012) J. Hong et al. DIABETES CARE
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
- (2011) Giovanni Musso et al. ANNALS OF MEDICINE
- Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
- (2011) Chrysi Koliaki et al. Diabetes Therapy
- Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials
- (2010) C. Lamanna et al. DIABETES OBESITY & METABOLISM
- Inflammatory cytokines in heart failure: roles in aetiology and utility as biomarkers
- (2010) L. Tamariz et al. EUROPEAN HEART JOURNAL
- Cardiovascular Outcomes in Trials of Oral Diabetes Medications
- (2008) Elizabeth Selvin et al. ARCHIVES OF INTERNAL MEDICINE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now